M.K. Parmar

Type de document

Co-auteur

J. Wagstaff

D. Tsang

S Tolan

G. Thalmann

M.R. Sydes

S. Sundar

J. Staffurth

R. Srinivasan

N. Srihari

M.R. Spears

J.M. Russell

A.J. Robinson

A.W. Ritchie

A. Protheroe

C. Peedell

C.C. Parker

O. Parikh

O'Sullivan, J.M.

R. Millman

D.B. McLaren

F. McKinna

D. Matheson

M.D. Mason

R. Laing

R. J. Jones

N.D. James

R. Hughes

J. Hetherington

J.D. Graham

S. Gibbs

J. Gale

T. Elliott

D.P. Dearnaley

J. de Bono

W. Cross

A. Cook

N.W. Clarke

S. Chowdhury

P. Chakraborti

R. Cathomas

S. Brock

A.J. Birtle

S. Beesley

G. Attard

C. Amos

M. Alzouebi

Date

Source

Serveur académique Lausannois (1)

Mot-clé

administration (1) temps (durée) (1) thérapie (1) norme (1) recherche (1) acide (1) danger (1) affectation (1) effet (1) dosage (1) maladie (1) âge (1) adulte (1) procès (1) cancer (1) survie (1) Testing (1) Treatment (1) Chemotherapy (1) Control (1) Cancer (1) Care (1) Methods (1) Docetaxel (1) Nineteen forties (1) Ci (Chinese poetry) (1) Time (1) Therapeutics (1) Testing (1) Swiss (1)

Documents écrit par M.K. Parmar (1) | parle de M.K. Parmar (0)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

N.D. James et al. (19 mars 2016)